Introduction:
MilliporeSigma, the U.S. and Canada life science business of Merck KGaA, has invested more than €300 million ($324.5 million) in a new bioprocessing production center in Daejeon, South Korea. The facility is expected to support biotechnology and pharmaceutical companies in process development, clinical research, and commercial manufacturing of biologics, including vaccines, cell and gene therapies, and protein-based therapies. The investment aims to foster collaboration and increase the speed of bringing new therapies to patients.
- MilliporeSigma has invested over €300 million in a new bioprocessing production center in South Korea.
- The facility is the largest investment by the company’s life science business sector in Asia-Pacific.
- The center will support biotechnology and pharmaceutical companies in process development, clinical research, and commercial manufacturing of biologics.
- The investment is expected to create approximately 300 additional jobs by the end of 2028.
- The goal is to foster collaboration with institutions in the Asia-Pacific region to accelerate the development of new therapies.
Conclusion:
MilliporeSigma’s investment in a new bioprocessing production center in South Korea reflects its commitment to advancing biotechnology and supporting the development of innovative therapies. The new facility will enhance the company’s presence in the Asia-Pacific region and create job opportunities. By collaborating with institutions in the region, MilliporeSigma aims to accelerate the development and delivery of new therapies to patients.
